Sarah Preis

Sarah Preis


Early Stage Researcher at Klinik und Poliklinik für Dermatologie und Allergologie am Biederstein


Dermatologie am Biederstein,
Biedersteiner Str. 29,
80802 Munich

Telefon: +49 89 4140 3024

Project Title

The role of gender differences in epidemiology and public health leveraging skin diseases

Research Interest

• Assessing gender-related differences of skin diseases in terms of epidemiology and public health, including but not limited to differences in disease prevalence, treatment response, prevention approaches and associated unmet needs
• Focusing on gender-biased disease management and recognizing unintended gender bias in patient care


PD Dr. med. Alexander Zink, PhD

Curriculum Vitae


since 2022           Ph.D. candidate in Medical Research: Epidemiology & Public Health, LMU Munich, Germany
                            Dermatologie und Allergologie am Biederstein, Technical
snce 07/2019      Resident Physician Klinik und Poliklinik für University of Munich
30/06/2019         Approbation Technical University of Munich
10/2012 -
04/2022              Medical Studies Albert-Ludwigs-Universität Freiburg, Technical University of Munich



Preis et al. "Dermatologische Akutfälle" Hautarzt 2022 Feb;73(2):160. doi: 10.1007/s00105-022-04945-2.

Preis et al: "Pantoea dispera associated folliculitis as a souvenir from a self-discovery in bat caves"- JAAD
Case Rep 2022 May 18;25:15-17.

Preis et. al: "Four-year-old boy with a spontaneously appearing plaque on his face" - JEADV Clinical Practice
06/2022, p. 138-141

Preis et al: "The Munich Atopy Predicition Study (MAPS): a prospective birth cohort addressing clinical and
molecular risk factors for atopic dermatitis in early childhood"-BMJ Open 2022;12:e059256. doi: 10.1136/

Schmitt, C, Preis, S: "Papeln, Plaques and Pruritus", Dermatologie (Heidelb)2022 Sep 21. doi: 10.1007/

Preis et al. ‘Plasmablastic lymphoma marked by hidradenitis suppurativa’ - JAAD Case Rep 2022 Jul 3;27:13-15. doi:10.1016/j.jdcr.2022.06.016.

Liu Y et al: "A Pair of Prognostic Biomarkers in Triple-Negative Breast Cancer: KLK10 and KLK11 mRNA
Expression" Life (Basel)2022 Sep 28;12(10):1517. doi:10.3390/life12101517.

Gong et al: "Prognostic value of kallikrein-related peptidase 12 (KLK12) mRNA expression in triple-negative
breast cancer patients", Mol Med 2020 Feb 7;26(1):19.

Loessner D et al: "Kallikrein-related peptidases represent attractive therapeutic targets for ovarian cancer",
Expert Opin Ther Targets 2018 Sep;22(9):745-763

Julia Miller et al.: "Differential tumor biological role of the tumor suppressor KAI1 and its splice variant in
human breast cancer cells" Oncotarget 2018 Jan 5;9(5):6369-6390.